Top

Published in:

Open Access 01-12-2012 | Research article

Arachidonic acid and cancer risk: a systematic review of observational studies

Authors: Mai Sakai, Saki Kakutani, Chika Horikawa, Hisanori Tokuda, Hiroshi Kawashima, Hiroshi Shibata, Hitomi Okubo, Satoshi Sasaki

Published in: BMC Cancer | Issue 1/2012

Abstract

Background

An n-6 essential fatty acid, arachidonic acid (ARA) is converted into prostaglandin E₂, which is involved in tumour extension. However, it is unclear whether dietary ARA intake leads to cancer in humans. We thus systematically evaluated available observational studies on the relationship between ARA exposure and the risk of colorectal, skin, breast, prostate, lung, and stomach cancers.

Methods

We searched the PubMed database for articles published up to May 17, 2010. 126 potentially relevant articles from the initial search and 49,670 bibliographies were scrutinised to identify eligible publications by using predefined inclusion criteria. A comprehensive literature search yielded 52 eligible articles, and their reporting quality and methodological quality was assessed. Information on the strength of the association between ARA exposure and cancer risk, the dose-response relationship, and methodological limitations was collected and evaluated with respect to consistency and study design.

Results

For colorectal, skin, breast, and prostate cancer, 17, 3, 18, and 16 studies, respectively, were identified. We could not obtain eligible reports for lung and stomach cancer. Studies used cohort (n = 4), nested case-control (n = 12), case-control (n = 26), and cross-sectional (n = 12) designs. The number of subjects (n = 15 - 88,795), ARA exposure assessment method (dietary intake or biomarker), cancer diagnosis and patient recruitment procedure (histological diagnosis, cancer registries, or self-reported information) varied among studies. The relationship between ARA exposure and colorectal cancer was inconsistent based on ARA exposure assessment methodology (dietary intake or biomarker). Conversely, there was no strong positive association or dose-response relationship for breast or prostate cancer. There were limited numbers of studies on skin cancer to draw any conclusions from the results.

Conclusions

The available epidemiologic evidence is weak because of the limited number of studies and their methodological limitations, but nonetheless, the results suggest that ARA exposure is not associated with increased breast and prostate cancer risk. Further evidence from well-designed observational studies is required to confirm or refute the association between ARA exposure and risk of cancer.

Available only for authorised users

World Health Organization: The global burden of disease: 2004 update. 2008, Geneva: WHO

International Agency for Research on Cancer: World Cancer Report 2008. 2008, Lyon: WHO

Prentice RL, Caan B, Chlebowski RT, Patterson R, Kuller LH, Ockene JK, Margolis KL, Limacher MC, Manson JE, Parker LM, Paskett E, Phillips L, Robbins J, Rossouw JE, Sarto GE, Shikany JM, Stefanick ML, Thomson CA, Van Horn L, Vitolins MZ, Wactawski-Wende J, Wallace RB, Wassertheil-Smoller S, Whitlock E, Yano K, Adams-Campbell L, Anderson GL, Assaf AR, Beresford SA, Black HR, Brunner RL, Brzyski RG, Ford L, Gass M, Hays J, Heber D, Heiss G, Hendrix SL, Hsia J, Hubbell FA, Jackson RD, Johnson KC, Kotchen JM, LaCroix AZ, Lane DS, Langer RD, Lasser NL, Henderson MM: Low-fat dietary pattern and risk of invasive breast cancer: the Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006, 295: 629-642. 10.1001/jama.295.6.629.CrossRefPubMed

Prentice RL, Anderson GL: The women’s health initiative: lessons learned. Annu Rev Publ Health. 2008, 29: 131-150. 10.1146/annurev.publhealth.29.020907.090947.CrossRef

International Agency for Research on Cancer: Cancer: causes, occurrence and control. 1990, Lyon: John Wiley & Sons, Ltd

Park SY, Murphy SP, Wilkens LR, Henderson BE, Kolonel LN: Fat and meat intake and prostate cancer risk: the multiethnic cohort study. Int J Cancer. 2007, 121: 1339-1345. 10.1002/ijc.22805.CrossRefPubMed

Beresford SA, Johnson KC, Ritenbaugh C, Lasser NL, Snetselaar LG, Black HR, Anderson GL, Assaf AR, Bassford T, Bowen D, Brunner RL, Brzyski RG, Caan B, Chlebowski RT, Gass M, Harrigan RC, Hays J, Heber D, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Jackson RD, Kotchen JM, Kuller LH, LaCroix AZ, Lane DS, Langer RD, Lewis CE, Manson JE, Margolis KL, Mossavar-Rahmani Y, Ockene JK, Parker LM, Perri MG, Phillips L, Prentice RL, Robbins J, Rossouw JE, Sarto GE, Stefanick ML, Van Horn L, Vitolins MZ, Wactawski-Wende J, Wallace RB, Whitlock E: Low-fat dietary pattern and risk of colorectal cancer: the Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006, 295: 643-654. 10.1001/jama.295.6.643.CrossRefPubMed

Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC: Intake of fat, meat, and fiber in relation to risk of colon cancer in men. Cancer Res. 1994, 54: 2390-2397.PubMed

Jaax S, Scott LW, Wolf JE, Thornby JI, Black HS: General guidelines for a low-fat diet effective in the management and prevention of nonmelanoma skin cancer. Nutr Canc. 1997, 27: 150-156. 10.1080/01635589709514517.CrossRef

10.

Black HS, Thornby JI, Wolf JE, Goldberg LH, Herd JA, Rosen T, Bruce S, Tschen JA, Scott LW, Jaax S, Foreyt JP, Reusser B: Evidence that a low-fat diet reduces the occurrence of non-melanoma skin cancer. Int J Cancer. 1995, 62: 165-169. 10.1002/ijc.2910620210.CrossRefPubMed

11.

Davies TW, Treasure FP, Welch AA, Day NE: Diet and basal cell skin cancer: results from the EPIC-Norfolk cohort. Br J Dermatol. 2002, 146: 1017-1022. 10.1046/j.1365-2133.2002.04763.x.CrossRefPubMed

12.

Mackie BS, Johnson AR, Mackie LE, Fogerty AC, Ferris M, Baxter RI: Dietary polyunsaturated fats and malignant melanoma. Med J Aust. 1980, 1: 159-163.PubMed

13.

James MJ, Gibson RA, Cleland LG: Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000, 71 (Suppl 1): 343S-348S.PubMed

14.

Calder PC: Polyunsaturated fatty acids, inflammation, and immunity. Lipids. 2001, 36: 1007-1024. 10.1007/s11745-001-0812-7.CrossRefPubMed

15.

Benatti P, Peluso G, Nicolai R, Calvani M: Polyunsaturated fatty acids: biochemical, nutritional and epigenetic properties. J Am Coll Nutr. 2004, 23: 281-302.CrossRefPubMed

16.

Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JR: Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis?. Lancet. 1978, 2: 117-119.CrossRefPubMed

17.

Funk CD: Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001, 294: 1871-1875. 10.1126/science.294.5548.1871.CrossRefPubMed

18.

Helliwell RJA, Adams LF, Mitchell MD: Prostaglandin synthase: recent developments and a novel hypothesis. Prostag Leukot Essent Fatty Acids. 2004, 70: 101-113. 10.1016/j.plefa.2003.04.002.CrossRef

19.

Lewis RA, Austen KF, Soberman RJ: Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med. 1990, 323: 645-655. 10.1056/NEJM199009063231006.CrossRefPubMed

20.

Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, Golanski J, Sitkiewicz D, Pregowski J, Gorski J, Zembala M, Opolski G, Huber K, Arnesen H, Kristensen SD, De Caterina R: Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2009, 30: 426-435.CrossRefPubMed

21.

Rostom A, Dubé C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D, US Preventive Services Task Force: Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007, 146: 376-389.CrossRefPubMed

22.

Dubé C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D, US Preventive Services Task Force: The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007, 146: 365-375.CrossRefPubMed

23.

Takkouche B, Regueira-Méndez C, Etminan M: Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Canc Inst. 2008, 100: 1439-1447. 10.1093/jnci/djn324.CrossRef

24.

Mahmud S, Franco E, Aprikian A: Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer. 2004, 90: 93-99. 10.1038/sj.bjc.6601416.CrossRefPubMedPubMedCentral

25.

Chiang N, Serhan CN, Dahlén SE, Drazen JM, Hay DWP, Rovati GE, Shimizu T, Yokomizo T, Brink C: The Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Action in Vivo. Pharmacol Rev. 2006, 58: 463-487. 10.1124/pr.58.3.4.CrossRefPubMed

26.

Petrik MB, McEntee MF, Chiu CH, Whelan J: Antagonism of Arachidonic Acid Is Linked to the Antitumorigenic Effect of Dietary Eicosapentaenoic Acid in Apc^Min/1 Mice. J Nutr. 2000, 130: 1153-1158.PubMed

27.

Imai N, Kawabe M, Tamano S, Doi Y, Nakashima H, Suguro M, Numano T, Hara T, Hagiwara A, Furukawa F, Kaneda Y, Tateishi N, Fujii W, Kawashima H, Shibata H, Sakakibara Y: Arachidonate-enriched triglyceride oil does not promote tumor development in a rat medium-term multi-organ carcinogenesis model. Food Chem Toxicol. 2012, 50: 2780-2791. 10.1016/j.fct.2012.05.004.CrossRefPubMed

28.

Lin J, Zhang SM, Cook NR, Lee IM, Buring JE: Dietary fat and fatty acids and risk of colorectal cancer in women. Am J Epidemiol. 2004, 160: 1011-1022. 10.1093/aje/kwh319.CrossRefPubMed

29.

Saadatian-Elahi M, Toniolo P, Ferrari P, Goudable J, Akhmedkhanov A, Zeleniuch-Jacquotte A, Riboli E: Serum fatty acids and risk of breast cancer in a nested case-control study of the New York University Women's Health Study. Canc Epidemiol Biomarkers Prev. 2002, 11: 1353-1360.

30.

Murff HJ, Shu XO, Li H, Dai Q, Kallianpur A, Yang G, Cai H, Wen W, Gao YT, Zheng W: A prospective study of dietary polyunsaturated fatty acids and colorectal cancer risk in Chinese women. Canc Epidemiol Biomarkers Prev. 2009, 18: 2283-2291. 10.1158/1055-9965.EPI-08-1196.CrossRef

31.

Nkondjock A, Shatenstein B, Maisonneuve P, Ghadirian P: Assessment of risk associated with specific fatty acids and colorectal cancer among French-Canadians in Montreal: a case-control study. Int J Epidemiol. 2003, 32: 200-209. 10.1093/ije/dyg048.CrossRefPubMed

32.

Caleffi M, Ashraf J, Rowe PH, Thomas BS, Fentiman IS: A comparison of the fatty acid profiles of subcutaneous fat from women with breast cancer, benign breast disease and normal controls. Anticancer Res. 1987, 7: 1305-1307.PubMed

33.

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007, 335: 806-808. 10.1136/bmj.39335.541782.AD.CrossRefPubMedPubMedCentral

34.

Hall MN, Campos H, Li H, Sesso HD, Stampfer MJ, Willett WC, Ma J: Blood levels of long-chain polyunsaturated fatty acids, aspirin, and the risk of colorectal cancer. Canc Epidemiol Biomarkers Prev. 2007, 16: 314-321. 10.1158/1055-9965.EPI-06-0346.CrossRef

35.

Kojima M, Wakai K, Tokudome S, Suzuki K, Tamakoshi K, Watanabe Y, Kawado M, Hashimoto S, Hayakawa N, Ozasa K, Toyoshima H, Suzuki S, Ito Y, Tamakoshi A, JACC Study Group: Serum levels of polyunsaturated fatty acids and risk of colorectal cancer: a prospective study. Am J Epidemiol. 2005, 161: 462-471. 10.1093/aje/kwi066.CrossRefPubMed

36.

Theodoratou E, McNeill G, Cetnarskyj R, Farrington SM, Tenesa A, Barnetson R, Porteous M, Dunlop M, Campbell H: Dietary fatty acids and colorectal cancer: a case-control study. Am J Epidemiol. 2007, 166: 181-195. 10.1093/aje/kwm063.CrossRefPubMed

37.

Slattery ML, Potter JD, Duncan DM, Berry TD: Dietary fats and colon cancer: assessment of risk associated with specific fatty acids. Int J Cancer. 1997, 73: 670-677. 10.1002/(SICI)1097-0215(19971127)73:5<670::AID-IJC10>3.0.CO;2-A.CrossRefPubMed

38.

Kuriki K, Wakai K, Hirose K, Matsuo K, Ito H, Suzuki T, Saito T, Kanemitsu Y, Hirai T, Kato T, Tatematsu M, Tajima K: Risk of colorectal cancer is linked to erythrocyte compositions of fatty acids as biomarkers for dietary intakes of fish, fat, and fatty acids. Canc Epidemiol Biomarkers Prev. 2006, 15: 1791-1798. 10.1158/1055-9965.EPI-06-0180.CrossRef

39.

Busstra MC, Siezen CL, Grubben MJ, van Kranen HJ, Nagengast FM, van't Veer P: Tissue levels of fish fatty acids and risk of colorectal adenomas: a case-control study (Netherlands). Canc Causes Contr. 2003, 14: 269-276. 10.1023/A:1023650201730.CrossRef

40.

Ghadimi R, Kuriki K, Tsuge S, Takeda E, Imaeda N, Suzuki S, Sawai A, Takekuma K, Hosono A, Tokudome Y, Goto C, Esfandiary I, Nomura H, Tokudome S: Serum concentrations of fatty acids and colorectal adenoma risk: a case-control study in Japan. Asian Pac J Canc Prev. 2008, 9: 111-118.

41.

Baró L, Hermoso JC, Núñez MC, Jiménez-Rios JA, Gil A: Abnormalities in plasma and red blood cell fatty acid profiles of patients with colorectal cancer. Br J Cancer. 1998, 77: 1978-1983. 10.1038/bjc.1998.328.CrossRefPubMed

42.

Neoptolemos JP, Thomas BS: Erythrocyte membrane stearic acid: oleic acid ratios in colorectal cancer using tube capillary column gas liquid chromatography. Ann Clin Biochem. 1990, 27: 38-43.CrossRefPubMed

43.

Neoptolemos JP, Clayton H, Heagerty AM, Nicholson MJ, Johnson B, Mason J, Manson K, James RF, Bell PR: Dietary fat in relation to fatty acid composition of red cells and adipose tissue in colorectal cancer. Br J Cancer. 1988, 58: 575-579. 10.1038/bjc.1988.262.CrossRefPubMedPubMedCentral

44.

Almendingen K, Høstmark AT, Fausa O, Mosdøl A, Aabakken L, Vatn MH: Familial adenomatous polyposis patients have high levels of arachidonic acid and docosahexaenoic acid and low levels of linoleic acid and alpha-linolenic acid in serum phospholipids. Int J Cancer. 2006, 120: 632-637.CrossRef

45.

Fernández-Bañares F, Esteve M, Navarro E, Cabré E, Boix J, Abad-Lacruz A, Klaassen J, Planas R, Humbert P, Pastor C, Gassull MA: Changes of the mucosal n3 and n6 fatty acid status occur early in the colorectal adenoma-carcinoma sequence. Gut. 1996, 38: 254-259. 10.1136/gut.38.2.254.CrossRefPubMedPubMedCentral

46.

Hietanen E, Bartsch H, Béréziat JC, Camus AM, McClinton S, Eremin O, Davidson L, Boyle P: Diet and oxidative stress in breast, colon and prostate cancer patients: a case-control study. Eur J Clin Nutr. 1994, 48: 575-586.PubMed

47.

Berry EM, Zimmerman J, Peser M, Ligumsky M: Dietary fat, adipose tissue composition, and the development of carcinoma of the colon. J Natl Canc Inst. 1986, 77: 93-97.

48.

Hakim IA, Harris RB, Ritenbaugh C: Fat intake and risk of squamous cell carcinoma of the skin. Nutr Canc. 2000, 36: 155-162. 10.1207/S15327914NC3602_3.CrossRef

49.

Harris RB, Foote JA, Hakim IA, Bronson DL, Alberts DS: Fatty acid composition of red blood cell membranes and risk of squamous cell carcinoma of the skin. Canc Epidemiol Biomarkers Prev. 2005, 14: 906-912. 10.1158/1055-9965.EPI-04-0670.CrossRef

50.

Mackie BS, Mackie LE, Curtin LD, Bourne DJ: Melanoma and dietary lipids. Nutr Canc. 1987, 9: 219-226. 10.1080/01635588709513930.CrossRef

51.

Holmes MD, Hunter DJ, Colditz GA, Stampfer MJ, Hankinson SE, Speizer FE, Rosner B, Willett WC: Association of dietary intake of fat and fatty acids with risk of breast cancer. JAMA. 1999, 281: 914-920. 10.1001/jama.281.10.914.CrossRefPubMed

52.

Voorrips LE, Brants HA, Kardinaal AF, Hiddink GJ, van den Brandt PA, Goldbohm RA: Intake of conjugated linoleic acid, fat, and other fatty acids in relation to postmenopausal breast cancer: the Netherlands Cohort Study on Diet and Cancer. Am J Clin Nutr. 2002, 76: 873-882.PubMed

53.

Pala V, Krogh V, Muti P, Chajès V, Riboli E, Micheli A, Saadatian M, Sieri S, Berrino F: Erythrocyte membrane fatty acids and subsequent breast cancer: a prospective Italian study. J Natl Canc Inst. 2001, 93: 1088-1095. 10.1093/jnci/93.14.1088.CrossRef

54.

Chajès V, Hultén K, Van Kappel AL, Winkvist A, Kaaks R, Hallmans G, Lenner P, Riboli E: Fatty-acid composition in serum phospholipids and risk of breast cancer: an incident case-control study in Sweden. Int J Cancer. 1999, 83: 585-590. 10.1002/(SICI)1097-0215(19991126)83:5<585::AID-IJC2>3.0.CO;2-Z.CrossRefPubMed

55.

Nkondjock A, Shatenstein B, Ghadirian P: A case-control study of breast cancer and dietary intake of individual fatty acids and antioxidants in Montreal, Canada. Breast. 2003, 12: 131-138.CrossRef

56.

Vatten LJ, Bjerve KS, Andersen A, Jellum E: Polyunsaturated fatty acids in serum phospholipids and risk of breast cancer: a case-control study from the Janus serum bank in Norway. Eur J Cancer. 1993, 29A: 532-538.CrossRefPubMed

57.

London SJ, Sacks FM, Stampfer MJ, Henderson IC, Maclure M, Tomita A, Wood WC, Remine S, Robert NJ, Dmochowski JR, Willett WC: Fatty acid composition of the subcutaneous adipose tissue and risk of proliferative benign breast disease and breast cancer. J Natl Canc Inst. 1993, 85: 785-793. 10.1093/jnci/85.10.785.CrossRef

58.

Zhu ZR, Ågren J, Männistö S, Pietinen P, Eskelinen M, Syrjänen K, Uusitupa M: Fatty acid composition of breast adipose tissue in breast cancer patients and in patients with benign breast disease. Nutr Canc. 1995, 24: 151-160. 10.1080/01635589509514403.CrossRef

59.

Aro A, Männistö S, Salminen I, Ovaskainen ML, Kataja V, Uusitupa M: Nutr Inverse association between dietary and serum conjugated linoleic acid and risk of breast cancer in postmenopausal women. Cancer. 2000, 38: 151-157.

60.

Zaridze DG, Chevchenko VE, Levtshuk AA, Lifanova YE, Maximovitch DM: Fatty acid composition of phospholipids in erythrocyte membranes and risk of breast cancer. Int J Cancer. 1990, 45: 807-810. 10.1002/ijc.2910450502.CrossRefPubMed

61.

Bagga D, Anders KH, Wang HJ, Glaspy JA: Long-chain n-3-to-n-6 polyunsaturated fatty acid ratios in breast adipose tissue from women with and without breast cancer. Nutr Canc. 2002, 42: 180-185. 10.1207/S15327914NC422_5.CrossRef

62.

Maillard V, Bougnoux P, Ferrari P, Jourdan ML, Pinault M, Lavillonnière F, Body G, Le Floch O, Chajès V: N-3 and n-6 fatty acids in breast adipose tissue and relative risk of breast cancer in a case-control study in Tours, France. Int J Cancer. 2002, 98: 78-83. 10.1002/ijc.10130.CrossRefPubMed

63.

Petrek JA, Hudgins LC, Levine B, Ho M, Hirsch J: Breast cancer risk and fatty acids in the breast and abdominal adipose tissues. J Natl Canc Inst. 1994, 86: 53-56. 10.1093/jnci/86.1.53.CrossRef

64.

Williams CM, Maunder K: Fatty acid compositions of inositol and choline phospholipids of breast tumours and normal breast tissue. Eur J Clin Nutr. 1993, 47: 260-267.PubMed

65.

Punnonen K, Hietanen E, Auvinen O, Punnonen R: Phospholipids and fatty acids in breast cancer tissue. J Cancer Res Clin Oncol. 1989, 115: 575-578. 10.1007/BF00391361.CrossRefPubMed

66.

Eid A, Berry EM: The relationship between dietary fat, adipose tissue composition, and neoplasms of the breast. Nutr Canc. 1988, 11: 173-177. 10.1080/01635588809513984.CrossRef

67.

Leitzmann MF, Stampfer MJ, Michaud DS, Augustsson K, Colditz GC, Willett WC, Giovannucci EL: Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer. Am J Clin Nutr. 2004, 80: 204-216.PubMed

68.

Männistö S, Pietinen P, Virtanen MJ, Salminen I, Albanes D, Giovannucci E, Virtamo J: Fatty acids and risk of prostate cancer in a nested case-control study in male smokers. Canc Epidemiol Biomarkers Prev. 2003, 12: 1422-1428.

69.

Schuurman AG, van den Brandt PA, Dorant E, Brants HA, Goldbohm RA: Association of energy and fat intake with prostate carcinoma risk: results from The Netherlands Cohort Study. Cancer. 1999, 86: 1019-1027. 10.1002/(SICI)1097-0142(19990915)86:6<1019::AID-CNCR18>3.0.CO;2-H.CrossRefPubMed

70.

Crowe FL, Allen NE, Appleby PN, Overvad K, Aardestrup IV, Johnsen NF, Tjønneland A, Linseisen J, Kaaks R, Boeing H, Kröger J, Trichopoulou A, Zavitsanou A, Trichopoulos D, Sacerdote C, Palli D, Tumino R, Agnoli C, Kiemeney LA, Bueno-de-Mesquita HB, Chirlaque MD, Ardanaz E, Larrañaga N, Quirós JR, Sánchez MJ, González CA, Stattin P, Hallmans G, Bingham S, Khaw KT, Rinaldi S, Slimani N, Jenab M, Riboli E, Key TJ: Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr. 2008, 88: 1353-1363.PubMed

71.

Chavarro JE, Stampfer MJ, Li H, Campos H, Kurth T, Ma J: A prospective study of polyunsatutated fatty acid levels in blood and prostate cancer risk. Canc Epidemiol Biomarkers Prev. 2007, 16: 1364-1370. 10.1158/1055-9965.EPI-06-1033.CrossRef

72.

Harvei S, Bjerve KS, Tretli S, Jellum E, Robsahm TE, Vatten L: Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer. Int J Cancer. 1997, 71: 545-551. 10.1002/(SICI)1097-0215(19970516)71:4<545::AID-IJC7>3.0.CO;2-U.CrossRefPubMed

73.

Gann PH, Hennekens CH, Sacks FM, Grodstein F, Giovannucci EL, Stampfer MJ: Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Canc Inst. 1994, 86: 281-286. 10.1093/jnci/86.4.281.CrossRef

74.

Hodge AM, English DR, McCredie MR, Severi G, Boyle P, Hopper JL, Giles GG: Foods, nutrients and prostate cancer. Canc Causes Contr. 2004, 15: 11-20.CrossRef

75.

Ukoli FA, Fowke JH, Akumabor P, Oguike T, Taher KA, Murff HJ, Amaefuna ER, Kittles R, Ahaghotu C, Osime U, Beech DJ: The association of plasma fatty acids with prostate cancer risk in African Americans and Africans. J Health Care Poor Underserved. 2010, 21 (Suppl 1): 127-147.CrossRefPubMed

76.

Ukoli FA, Akumabor PN, Oguike TC, Dent LL, Beech D, Osime U: The association of plasma fatty acids with prostate cancer risk in Nigerians. Ethn Dis. 2009, 19: 454-461.PubMed

77.

Newcomer LM, King IB, Wicklund KG, Stanford JL: The association of fatty acids with prostate cancer risk. Prostate. 2001, 47: 262-268. 10.1002/pros.1070.CrossRefPubMed

78.

Yang YJ, Lee SH, Hong SJ, Chung BC: Comparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia. Clin Biochem. 1999, 32: 405-409. 10.1016/S0009-9120(99)00036-3.CrossRefPubMed

79.

Faas FH, Dang AQ, White J, Schaefer RF, Johnson DE: Decreased prostatic arachidonic acid in human prostatic carcinoma. BJU Int. 2003, 92: 551-554. 10.1046/j.1464-410X.2003.04387.x.CrossRefPubMed

80.

Chaudry A, McClinton S, Moffat LE, Wahle KW: Essential fatty acid distribution in the plasma and tissue phospholipids of patients with benign and malignant prostatic disease. Br J Cancer. 1991, 64: 1157-1160. 10.1038/bjc.1991.481.CrossRefPubMedPubMedCentral

81.

Mamalakis G, Kafatos A, Kalogeropoulos N, Andrikopoulos N, Daskalopulos G, Kranidis A: Prostate cancer vs hyperplasia: relationships with prostatic and adipose tissue fatty acid composition. Prostag Leukot Essent Fatty Acids. 2002, 66: 467-477. 10.1054/plef.2002.0384.CrossRef

82.

Kobayashi M, Sasaki S, Kawabata T, Hasegawa K, Tsugane S, JPHC: Validity of a self-administered food frequency questionnaire used in the 5-year follow-up survey of the JPHC Study Cohort I to assess fatty acid intake: comparison with dietary records and serum phospholipid level. J Epidemiol. 2003, 13 (Suppl 1): S64-S81.CrossRefPubMed

83.

Elmadfa I, Kornsteiner M: Fats and Fatty Acid Requirements for Adults. Ann Nutr Metab. 2009, 55: 56-75. 10.1159/000228996.CrossRefPubMed

84.

Kawabata T, Hirota S, Hirayama T, Adachi N, Hagiwara C, Iwama N, Kamachi K, Araki E, Kawashima H, Kiso Y: Age-related changes of dietary intake and blood eicosapentaenoic acid, docosahexaenoic acid, and arachidonic acid levels in Japanese men and women. Prostag Leukot Essent Fatty Acids. 2011, 84: 131-137. 10.1016/j.plefa.2011.01.001.CrossRef

85.

Arab L: Biomarkers of Fat and Fatty Acid Intake. J Nutr. 2003, 133 (Suppl 3): 925S-932S.PubMed

86.

Garland M, Sacks FM, Colditz GA, Rimm EB, Sampson LA, Willett WC, Hunter DJ: The relation between dietary intake and adipose tissue composition of selected fatty acids in US women. Am J Clin Nutr. 1998, 67: 25-30.PubMed

87.

Kakutani S, Ishikura Y, Tateishi N, Horikawa C, Tokuda H, Kontani M, Kawashima H, Sakakibara Y, Kiso Y, Shibata H, Morita I: Supplementation of arachidonic acid-enriched oil increases arachidonic acid contents in plasma phospholipids, but does not increase their metabolites and clinical parameters in Japanese healthy elderly individuals: a randomized controlled study. Lipids Health Dis. 2011, 10: 241-10.1186/1476-511X-10-241.CrossRefPubMedPubMedCentral

88.

Chen Y, Hao H, He S, Cai L, Li Y, Hu S, Ye D, Hoidal J, Wu P, Chen X: Lipoxin A4 and Its Analogue Suppress the Tumor Growth of Transplanted H22 in Mice: The Role of Antiangiogenesis. Mol Cancer Ther. 2011, 9: 2164-2174.CrossRef

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/606/prepub

Title: Arachidonic acid and cancer risk: a systematic review of observational studies
Authors: Mai Sakai
Saki Kakutani
Chika Horikawa
Hisanori Tokuda
Hiroshi Kawashima
Hiroshi Shibata
Hitomi Okubo
Satoshi Sasaki
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-12-606

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study

Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer

Conditional survival of cancer patients: an Australian perspective

Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas

Time trends of cancer mortality among elderly in Italy, 1970–2008: an observational study

Rationale and design of a multicenter prospective cohort study for the eVALuation and monitoring of HPV infections and relATEd cervical diseases in high-risk women (VALHIDATE study)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer